Study finds new method to deliver nanotech-based drugs

Susheela Srinivas Bengaluru | Updated on August 26, 2019 Published on August 26, 2019

Dr. Pabha Garg and Navneet Kumar from NIPER

Nanotechnology is increasingly being explored to deliver drugs. Efficient transfer of drugs to desired sites in the body, however, would require nano-based drugs to be able to penetrate biological barriers such as intestine barrier, blood-brain barrier and blood-retinal barrier.

Now an international group of scientists has found that nano-based drugs could be effectively delivered by hitchhiking on the same transport mechanism that is used to carry iron in the body, without disrupting the natural process.

The new process utilises small molecules called ligands, in this case, Gambogic Acid, that can latch on to a body protein called transferrin receptor, and deliver the drug effectively. The receptor is concentrated at the interface of different physiological barriers, particularly the human gut, and is known to regulate iron levels by facilitating binding of iron to another blood plasma protein called transferrin. The study focused on this protein because it may enable injectable drugs used for diabetes and cancer to be administrated via the oral method.

Preliminary results in studies done in rats showed that it significantly improved the absorption of nanoparticles across physiological barriers without being toxic or altering any other physiological processes.

In their previous studies, the scientists had used natural biological ligands and coated them on nanoparticles. However, they had found that these interfered with drug delivery as ligand-polymer drug carriers were outnumbered by native ligands. In the new study, they used Gambogic Acid, which has a high affinity to the transferrin receptor, as an alternative ligand.

“Gambogic Acid is not produced in the body. It is a different category plant derivative that binds to transferrin receptor.We have found that it did not compete with the natural ligands in the body. Clearly this strategy of non-competitive targeting seems to be superior to conventional targeted nanoparticles for its ability to bind to transferrin and facilitate better drug delivery,” explained Dr M N V Ravi Kumar, lead researcher of the study and professor at the Texas A&M Irma Lerma Rangel College of Pharmacy, while speaking to India Science Wire.

The scientists had coupled Gambogic Acid to a naturally degradable polymer called PLGA, such that cellular entry points were created for GA to latch on to the transferrin receptor, and processed them into particles of 200-250 nanometers size. The researchers used curcumin (turmeric compound) as the core drug for the study, which was encapsulated in the nanoparticles.

The Indian researchers in the study team, led by Dr. Prabha Garg of the National Institute of Pharmaceutical Education and Research (NIPER) at Mohali in Punjab, performed computational simulations to investigate the exact molecular binding location of GA with the receptor.

Navneet Kumar, PhD scholar and team member, who was involved in the molecular analysis said, “We used different binding site prediction tools, molecular docking and all-atom molecular dynamics simulations and found that the binding site of Gambogic Acid is at an independent interface from that of the transferrin binding site.”

Besides, M N V Ravi Kumar, the team included Meenakshi Arora, Raghu Ganugula, Gagandeep Kaur and Jean-Philippe Pellois from Texas A & M University; and Prabha Garg and Navneet Kumar from NIPER.

The results were published in the journal ACS Applied Biomaterials.

(India Science Wire)

Twitter handle: @sushisree

Published on August 26, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.